Faktor-XI-Hemmer in der Neurologie

Faktor-XI-Hemmer erheben den Anspruch, bei vergleichbarer Wirksamkeit wie bei den bisherigen Antikoagulanzien zu einem geringeren Risiko für Blutungsereignisse zu führen. Der Artikel stellt Studien vor, die sich dieser Fragestellung angenommen haben.

Schlüsselwörter

Gerinnungshemmer - Faktor-XI-Inhibitor - Schlaganfallprävention - Antikoagulation

• Literatur

• 1 Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost 2017; 117: 1283-1288
• 2 Gomez-Outes A, Alcubilla P, Calvo-Rojas G. et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol 2021; 77: 2987-3001
• 3 Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost 2013; 39: 621-631
• 4 Sharman Moser S, Chodick G, Ni YG. et al. The association between factor XI deficiency and the risk of bleeding, cardiovascular, and venous thromboembolic events. Thromb Haemost 2022; 122: 808-817
• 5 Wang X, Cheng Q, Xu L. et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3: 695-702
• 6 Greco A, Laudani C, Spagnolo M. et al. Pharmacology and clinical development of factor XI inhibitors. Circulation 2023; 147: 897-913
• 7 Piccini JP, Caso V, Connolly SJ. et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022; 399: 1383-1390
• 8 Piccini JP, Patel MR, Steffel J. et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2024; 236: 236-239
• 9 Ruff C. The AZALEA-TIMI 71 study and the future of factor XI inhibition: reflections from the American Heart Association Scientific Congress 2023. EMJ Cardiol 2024; 12 (Suppl. 01) 2-8
• 10 Diener HC, Rothwell PM. Antithrombotic drugs in secondary stroke prevention: still some way to go. Lancet 2022; 400: 974-975
• 11 Salomon O, Steinberg DM, Koren-Morag N. et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-4117
• 12 Sharma M, Molina CA, Toyoda K. et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2024; 23: 46-59
• 13 Sharma M, Molina CA, Toyoda K. et al. Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis 2022; 31: 106742
• 14 Shoamanesh A, Mundl H, Smith EE. et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400: 997-1007
• 15 Shoamanesh A, Mundl H, Smith EE. et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400: 997-1007
• 16 Weitz JI, Fredenburgh JC. 2017 scientific sessions sol sherry distinguished lecture in thrombosis: factor XI as a target for new anticoagulants. Arterioscler Thromb Vasc Biol 2018; 38: 304-310
• 17 Lassen MR, Raskob GE, Gallus A. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815
• 18 Lassen MR, Gallus A, Raskob GE. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498
• 19 Presume J, Ferreira J, Ribeiras R. Factor XI inhibitors: a new horizon in anticoagulation therapy. Cardiol Ther 2024; 13: 1-16
• 20 Presume J, Ferreira J, Ribeiras R. et al. Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery-Systematic review and meta-analysis. J Thromb Haemost 2022; 20: 2930-2938
• 21 Schäfer A. Antithrombotische Therpapie beim akuten Koronarsyndrom. Dtsch Med Wochenschr 2024; 149: 496-501
• 22 Rao SV, Kirsch B, Bhatt DL. et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 2022; 146: 1196-1206
• 23 Eikelboom J, Floege J, Thadhani R. et al. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney Int 2021; 100: 1199-1207
• 24 Diener HC, Aisenberg J, Ansell J. et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2017; 38: 860-868
• 25 De Vriese AS, Caluwé R, Van Der Meersch H. et al. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol 2021; 32: 1474-1483